NASDAQ$GBIO
Generation Bio Co · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Generation Bio reported first quarter 2023 financial results, highlighted by a strategic collaboration with Moderna and a cash balance expected to fund operations into 2025.
Generation Bio reported a net loss of $32.1 million for the first quarter of 2023. The company's cash balance of $288.6 million is expected to fund operations into 2025. A strategic collaboration with Moderna was also announced.
- Entered into a strategic collaboration with Moderna for liver disease programs and immune cell targeting.
- Factor VIII expression data in non-human primates for the hemophilia A program is expected in 2023.
- Cash balance of $288.6 million as of Q1 2023 is expected to fund operations into 2025.
- Received an additional $47.5 million from the Moderna collaboration in the second quarter of 2023.
Headline financials
Revenue & EPS history
Generation Bio · Revenue · Quarterly
$1.59M
Revenue by segment
Generation Bio · $2.15M total across 1 segment · Q3 2023
- Collaboration revenue$2.15M—100.0%
Forward guidance
The company anticipates that subsequent events and developments will cause the company’s views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q1 2023
+3.8%
Avg return
Earnings day
+5.9%
Avg return
5 days after
+8.6%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+61.7%
Q2 2025
Best reaction
-19.7%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -3.3% | +11.0% | +2.7% | |
| Q2 2025 | +61.7% | +62.0% | +46.9% | |
| Q1 2025 | +4.5% | +0.4% | +4.0% | |
| Q4 2024 | -3.7% | -14.3% | -9.5% | |
| Q3 2024 | +8.7% | -0.5% | -40.8% | |
| Q2 2024 | -2.0% | -3.7% | -10.2% | |
| Q1 2024 | +18.4% | +16.4% | +1.9% | |
| Q4 2023 | +3.1% | +11.5% | +39.4% | |
| Q3 2023 | -1.7% | +7.7% | +46.2% | |
| Q2 2023 | -5.3% | -7.0% | +6.8% | |
| Q1 2023 | -5.0% | -2.7% | +0.4% | |
| Q4 2022 | -8.4% | -10.0% | +15.5% | |
| Q3 2022 | +12.2% | — | — | |
| Q2 2022 | +7.7% | — | — | |
| Q1 2022 | -19.7% | — | — | |
| Q4 2021 | +21.1% | — | — | |
| Q3 2021 | -1.5% | — | — | |
| Q2 2021 | -6.2% | — | — | |
| Q1 2021 | +0.3% | — | — | |
| Q4 2020 | -0.9% | — | — | |
| Q3 2020 | +8.5% | — | — | |
| Q4 2019 | -0.5% | — | — | |
| Q2 2020 | -0.5% | — | — | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro